




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 9/20, 31/43</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 95/28148</b> <b>(43) International Publication Date:</b> 26 October 1995 (26.10.95)
<p><b>(21) International Application Number:</b> PCT/EP95/01269</p> <p><b>(22) International Filing Date:</b> 7 April 1995 (07.04.95)</p> <p><b>(30) Priority Data:</b>            9407386.3 14 April 1994 (14.04.94) GB</p> <p><b>(71) Applicant (for all designated States except US):</b> SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).</p> <p><b>(72) Inventors; and</b>  <b>(75) Inventors/Applicants (for US only):</b> GRIMMETT, Francis, Walter [GB/GB]; SmithKline Beecham Pharmaceuticals, Clarendon Road, Worthing, West Sussex BN14 8QH (GB). DAVIDSON, Nigel, Philip, McCreath [GB/US]; SmithKline Beecham Pharmaceuticals, Bristol Industrial Park, Weaver Pike, Bristol, TN 37620 (US).</p> <p><b>(74) Agent:</b> WALKER, Ralph, Francis; SmithKline Beecham, Corporate Intellectual Property, SB House, Great West Road, Brentford, Middlesex TW8 9BD (GB).</p>		<p><b>(81) Designated States:</b> JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p><b>Published</b>  <i>With international search report.</i></p>

**(54) Title:** PHARMACEUTICAL FORMULATION**(57) Abstract**

A tablet formulation which comprises a core containing a pharmaceutically active material, coated with a release retarding coating, surrounded by a casing layer which includes a second pharmaceutically active material.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

### Pharmaceutical Formulation

This invention relates to tablet formulations for oral administration, particularly to formulations, which comprise a  $\beta$ -lactam antibiotic, optionally  
5 together with a  $\beta$ -lactamase inhibitor.

Many known tablet formulations which include a  $\beta$ -lactam antibiotic are required to be taken orally three times a day. There is a need for oral formulations which need only be taken twice or less often per day. Methods of forming delayed or sustained release tablet formulations are known, for example coating the tablet  
10 with a release-retarding coating, or coating individual granules with such a coating, and compressing these coated granules into a tablet. "Release-retarding" as used herein, unless otherwise defined, refers both to release which is retarded so as to be sustained, i.e. active material is released gradually from the tablet, and to release which is retarded so as to be delayed, i.e. release begins or the rate of release  
15 increases after an initial delay.

Particular problems occur in the preparation of delayed or sustained release forms of the known antibacterial combination of the  $\beta$ -lactam antibiotic amoxycillin, in the form of its trihydrate, and the  $\beta$ -lactamase inhibitor clavulanic acid, in the form of an alkali metal salt, such as potassium clavulanate. This is because  
20 amoxycillin trihydrate is relatively insoluble in aqueous media, whereas potassium clavulanate is extremely soluble, hygroscopic and moisture-sensitive, and it is difficult to achieve sustained or delayed release of two such components at a compatible rate from a single formulation containing both.

According to this invention, a tablet formulation comprises a core which  
25 includes a first pharmaceutically active material, the core being coated with a release retarding coating, the coated core being itself surrounded by a casing layer which includes a second pharmaceutically active material.

The tablet formulation of the invention is suitable for oral administration, and provides a sustained and/or delayed release as a result of initial quick release of  
30 the second active material from the casing layer, and a sustained or delayed release of first active material from the coated core. Also the casing layer may serve to protect the core from the ingress of air and atmospheric moisture. Also coating of a single relatively large core in the tablet of the invention with a release-retarding coating requires less coating material than is required to coat a large number of  
35 smaller granules, and can therefore lead to a relatively low tablet weight.

The first and second pharmaceutically active materials in the tablet formulation may each individually, and/or together, comprise a  $\beta$ -lactam antibiotic optionally together with a  $\beta$ -lactamase inhibitor. Suitably the  $\beta$ -lactam antibiotic may be amoxycillin, e.g. in the form of its trihydrate, optionally together in

combination with the  $\beta$ -lactamase inhibitor clavulanate, (the term "clavulanate" used herein, unless otherwise identified, refers both to clavulanic acid and its salts) e.g. in particular potassium clavulanate. The first and second active materials may both comprise the same active material, for example both comprising a  $\beta$ -lactam

- 5 antibiotic optionally in combination with a  $\beta$ -lactamase inhibitor. When both the first and second active materials comprise amoxycillin and clavulanate, the relative ratios of amoxycillin: clavulanate may be different in the core and the casing layer, making up the overall ratio in the tablet.

- The amoxycillin: clavulanate ratios in the core and casing layer and the  
10 overall ratio may each vary between broad limits, e.g. between 30:1 to 1:1, typically 12:1 to 2:1. A preferred ratio is around 8:1 to 4:1  $\pm$ 25%.

- The quantity of active material(s) in the tablet may vary up to the maximum allowed daily dose, and may typically be around a nominal single unit dose. For example in the case of amoxycillin and clavulanate, a single tablet may contain  
15 around 125, 250, 500, 750 or 875 mg of amoxycillin, and 62.5, 125 or 250 mg of clavulanate, both sets of weights being expressed in terms of the respective free acids. Typically the overall tablet may contain nominally 500mg amoxycillin and 125 mg clavulanate, or 875mg amoxycillin and 125 mg of clavulanate. Alternatively these weights may be divided between two or more tablets.

- 20 Typically for example the core may contain 25-75% of the total weight of the first and second components, and the casing layer may contain 75-25% thereof.

- In the case of amoxycillin and clavulanate, in one embodiment both the core and the casing layer may contain clavulanate and amoxycillin. For example the core may contain 25-75% of the clavulanate and 25-75% of the amoxycillin, the balance  
25 being contained in the casing layer. For example the core may contain 100-400mg of amoxycillin and 30-95mg of clavulanate, expressed as the respective free acids. In an alternative embodiment, all of the clavulanate may be contained in the casing layer, e.g. in a rapid release form, with none of the clavulanate contained in the core. Such an embodiment may assist in maximising the clavulanate plasma level  
30 peak. In another alternative embodiment, all of the clavulanate may be contained in the core, with none of the clavulanate contained in the casing layer.

- The core may be any convenient shape and need not necessarily be directly related to the shape of the overall tablet, typically the core may be spherical, ellipsoidal, or oblate spheroidal, within any suitable or convenient, e.g. a  
35 conventional, tablet shape.

The core and the casing layer may both comprise a compact of compressed ingredients including the respective active materials such as amoxycillin trihydrate optionally combined with potassium clavulanate. The active material(s) in the core may be present in a micronised or solubilised form. In addition to active materials

the core and casing layer may contain additives conventional to the art of compressed tablets. Appropriate additives in such a tablet may comprise dihuents such as calcium carbonate, magnesium carbonate, dicalcium phosphate or mixtures thereof, binders such as microcrystalline cellulose hydroxypropylmethylcellulose, 5 hydroxypropyl- cellulose, polyvinylpyrrolidone, pre-gelatinised starch or gum acacia or mixtures thereof, disintegrants such as microcrystalline cellulose (fulfilling both binder and disintegrant functions) cross-linked polyvinylpyrrolidone, sodium starch glycollate, croscarmellose sodium or mixtures thereof, lubricants, such as magnesium stearate or stearic acid, glidants or flow aids, such as colloidal silica, 10 talc or starch, and stabilisers such as desiccating amorphous silica, colouring agents, flavours etc.. The core and casing layer may contain the same or different additives, in the same or different proportions.

The core may be made from a compacted mixture of its components, suitably in the form of granules, which may be made by a conventional granulating 15 process as known in the art. Preferably the granules are made by a procedure of dry granulation of the granule components, for example milling, blending, slugging then milling, or by milling, blending or roller compaction then milling. The granules may include conventional additives introduced as a result of the granulation process, e.g. lubricants such as magnesium stearate, in conventional quantities, e.g. ca. 0.5 - 20 1 wt% of magnesium stearate. Suitably the granules are of 10 - 80 mesh size, suitably 10-40 mesh size, for example 16 - 30 mesh size.

The release-retarding coating may be a polymeric material, for example an enteric polymer (the term "enteric polymer" is a term of the art referring to a polymer which is preferentially soluble in the less acid environment of the intestine 25 relative to the more acid environment of the stomach).

An enteric coating may be an essentially conventional coating material, for example enteric polymers such as cellulose acetate phthalate, cellulose acetate succinate, methylcellulose phthalate, ethylhydroxycellulose phthalate, polyvinyl- acetatephthalate, polyvinylbutyrate acetate, vinyl acetate-maleic anhydride 30 copolymer, styrene-maleic mono-ester copolymer, methyl acrylate-methacrylic acid copolymer, methacrylate-methacrylic acid-octyl acrylate copolymer, etc. These may be used either alone or in combination, or together with other polymers than those mentioned above. The enteric coating may also include insoluble substances which are neither decomposed nor solubilized in living bodies, such as alkyl 35 cellulose derivatives such as ethyl cellulose, crosslinked polymers such as styrene-divinylbenzene copolymer, polysaccharides having hydroxyl groups such as dextran, cellulose derivatives which are treated with bifunctional crosslinking agents such as epichlorohydrin, dichlorohydrin, 1, 2-, 3, 4-diepoxybutane, etc. The enteric coating may also include starch and/or dextrin.

Preferred coating materials are the pharmaceutically acceptable methacrylic acid copolymer which are copolymers, anionic in character, based on methacrylic acid and methyl methacrylate, for example having a ratio of free carboxyl groups : methyl-esterified carboxyl groups of 1 : >3, e.g. around 1 : 1 or 1 : 2, and with a mean molecular weight of 135000.

Such polymers are sold under the trade name Eudragit™, such as the Eudragit L series e.g. Eudragit L 12.5™, Eudragit L 12.5P™, Eudragit L100™, Eudragit L 100-55™, Eudragit L-30™, Eudragit L-30 D-55™, the Eudragit S™ series e.g. Eudragit S 12.5, Eudragit S 12.5P™, Eudragit S100™, the Eudragit NE™ series e.g. Eudragit NE 30D™, the Eudragit RL™ series, e.g. Eudragit RL 12.5™, Eudragit RL 100™, Eudragit RL PO™, Eudragit RL 30D™, and the Eudragit RS™ series e.g. Eudragit RS 12.5™, Eudragit RS 100™, Eudragit RS PO™, and Eudragit RS 30D™.

Some of these polymers are known and sold as enteric polymers, for example having a solubility in aqueous media at pH 5.5 and above, such as the commercially available "Eudragit" (Trade Mark) enteric polymers, such as "Eudragit L 30" (Trade Mark) i.e. a cationic polymer synthesised from dimethylaminoethyl methacrylate, "Eudragit S" (Trade Mark) and "Eudragit NE" (Trade Mark).

Such polymers may be used either alone or with a plasticiser. Such coatings are normally applied using a liquid medium, and the nature of the plasticiser depends upon whether the medium is aqueous or non-aqueous. Aqueous plasticisers include propylene glycol or "Citroflex" or Citroflex A2" (Trade Marks) (mainly triethyl citrate or acetyl triethyl citrate). Non-aqueous plasticisers include these, and also diethyl and dibutyl phthalate and dibutyl sebacate.

The quantity of plasticiser included will be apparent to those skilled in the art. The enteric coating may also include an anti-tack agent such as talc, silica or glyceryl monostearate. The quantity of plasticiser and anti-tack agent may be generally conventional to the art. Typically the coating may include around 10 - 25 wt. % plasticiser and up to around 50 wt% of anti tack agent, e.g. 5 - 20 wt. % of anti-tack agent.

An enteric coating may be applied to the core by dissolving or suspending the enteric coating materials in a suitable medium, such as water, methanol, ethanol, isopropanol, acetone, methyl ethyl ketone, methylene chloride, ethylene chloride, ethyl acetate, etc. or mixtures thereof, and the resultant solution or suspension may be sprayed on the core to coat them, followed by drying sufficiently with an air flow and screening.

In the case of the preferred enteric coating material referred to above, the enteric coating material may be dissolved or suspended in a solvent for example

water and coated onto the core using a fluidised bed system. If water is used, preferably an anti-foaming agent such as activated polymethylsiloxane is also included.

It may be desirable, particularly in the case of cores which contain highly soluble or moisture sensitive active materials such as potassium clavulanate, to first apply one or more sub-coats to the core, before application of the release retarding coating layer, the sub-coat consequently lying beneath the release retarding coating. Suitable sub-coat materials include hydroxypropylmethyl cellulose, for example of the known types E5 and E15 (Trade Marks) in mixture. It may also be desirable to apply one or more over-coats after application of the release retarding coating layer, the over-coat consequently lying over the release retarding coating. Suitable over-coat materials include copolymers of methacrylic acid and methyl methacrylate, and hydroxypropylmethyl cellulose. The over-coat may be of the same material as the sub-coat. Typically such coatings may be applied by known techniques of aqueous film coating.

The casing layer may be applied to the coated core by a generally conventional process in which the coated core is encased in a mass of the powdered or granulated casing material components. The granules of such a casing material may be made by a conventional granulating process as known in the art, and as discussed above with reference to the manufacture of the core granules.

The casing layer itself may be coated with a final outer coating, for example of hydroxypropyl methyl cellulose, which may be applied by known film coating techniques in a similar manner to the way in which the sub-and over-coats may be applied to the core.

The tablet of the invention offers the advantages effect that the active material in the casing layer is released initially in the stomach, and the coated core releases its active material content more slowly. In this way as *in vivo* decay of the initially released material occurs, active material is subsequently released from the core to provide an extended blood level profile. If the release-retarding coating on the core is an enteric coating the release of active material from the core may occur in the intestine.

The invention therefore also provides a method of preparing a pharmaceutical formulation as described herein, comprising the steps of forming a core which includes a first pharmaceutically active material, the core being coated with a release-retarding coating, then coating the core with a casing layer which includes a second pharmaceutically active material.

Clavulanic acid and its derivatives, e.g. salts such as potassium clavulanate are extremely moisture sensitive, and all operations carried out to prepare granules and formulations of this invention which contain clavulanate should be carried out

under conditions of low relative humidity, e.g. less than 30% RH, ideally as low as practical.

The present invention also provides a pharmaceutical formulation as described herein for use as an active therapeutic substance.

- 5       The present invention also provides a pharmaceutical formulation as described herein for use in the treatment of bacterial infections.

The present invention also provides the use of a formulation as described herein in the manufacture of a medicament for use in the treatment of bacterial infections.

- 10       The present invention also provides a method of treatment of bacterial infections in humans or animals which comprises the administration of an effective amount of a pharmaceutical formulation as described herein.

The invention will now be described by way of example only, with reference to Fig.1 which shows a cross-section through a tablet of the invention.

- 15       Referring to Fig 1, a tablet (overall (1)) comprises a core (2), which is coated with successively a sub-coat (3), an enteric coat (4), and an over-coat (5). The coated core (2-5) is itself encased within a casing layer (6) forming the overall shape of the tablet (1), and the casing layer (6) is itself coated with a protective film coat (7). The relative sizes of the core (2) and tablet (1), and the thickness of the  
20       coating layers (3), (4), (5), (6), (7) are not to scale but merely illustrative.

#### **Example 1**

Tablets 1 and 2 were prepared respectively being tablets containing nominally 500mg and 875mg of amoxycillin as the trihydrate, both tablets containing 125mg of clavulanate, as potassium clavulanate.



**Core.**

The core for tablets 1 and 2 had the same composition and was made by the same procedure. Their formulation was as below:

Component	mg	%	% Range* (mg range)
Amoxycillin trihydrate equivalent to Amoxycillin	250	55.56	22.2 - 88.8 (100mg - 400mg)
Potassium Clavulanate equivalent to Clavulanic Acid	62.5	13.90	6.94 - 20.8 (30mg - 95mg)
Polyplasdone XL dried	23.0	5.10	1.0 - 20.0
Syloid AL1	23.0	5.10	1.0 - 20.0
Magnesium Stearate	4.5	1.0	0.2 - 2.0
Microcrystalline Cellulose	450.0	100.0	400mg. - 900mg to

- 5           The Polyplasdone XL dried is present as a disintegrant. The Syloid AL1 is a desiccant to prevent hydrolytic degradation of the actives. The magnesium stearate is present as a lubricant. The microcrystalline cellulose is a tablet binder and disintegrant.

\*The % range column suggests suitable % ranges for the components listed.

- 10           The cores were made by the following process:

1.   **Granulation**

- 1.1   The amoxycillin trihydrate was milled using a swing hammer mill at fast speed through a 0.063" screen with knives forward.
- 1.2   The milled amoxycillin trihydrate was mixed with the potassium clavulanate, Polyplasdone, Syloid AL1, part of the magnesium stearate, and part of the microcrystalline cellulose.
- 15   1.3   The blend from 1.2 was slugged or roller compacted
- 1.4   The compacts or flake from 1.3 was milled through a swing hammer mill at medium speed with knives forward and fitted with an 0.063" screen.

20

2.   **Compaction**

	%
Compacted Granules from 1.4	94.5
Magnesium Stearate	0.5
Microcrystalline Cellulose	5.0

- 2.1 Granules from 1.4 were blended with remaining Magnesium Stearate and remaining Microcrystalline cellulose.
- 2.2. The cores were manufactured from the compression mix prepared in 2.1 to a core weight of 450mg, and a hardness of 15-20Kp Schleuniger.
- 5 2.3 The cores were then film sub-coated with an aqueous suspension of hydroxypropyl methyl cellulose, further coated with an Eudragit enteric coating and finally, with a further over-coating of hydroxypropyl methyl cellulose.

**Hydroxypropyl methyl cellulose core subcoat and over coat:**

	%
Hydroxypropyl methyl cellulose E5	4.95
Hydroxypropyl methyl cellulose E15	1.65
Polyethylene Glycol 6000	0.98
Polyethylene Glycol 4000	0.98
Titanium Dioxide	6.45
Purified Water PhEur	to 100.0

10

A coat weight of 18mg was applied to the core.

**Eudragit film coat formula:**

	%
Eudragit L30D (Trade Mark)	15.00
Antifoam M (Trade Mark)	0.15
Acetyl Triethyl Citrate	2.25
Talc Micronised	3.00
Pumped Water	to 100.00

15

- An enteric coat weight of 21.2mg was applied to the core. A 5mg/tablet final over-coat of the cores with a hydroxypropyl methyl cellulose coating was applied. The three film coats were applied to the core using low humidity conditions to effect rapid drying, in a coating drum (Accelacota, Driam or Hicota),
- 20 using an intermittent air spray process.

**Preparation of tablets incorporating cores from above.**

**Tablet 1**

- 500mg of Amoxycillin as Amoxycillin Trihydrate.
- 25 125mg Clavulanic Acid as Potassium Clavulanate.

Component	mg/tab	%
Amoxycillin trihydrate equivalent to Amoxycillin	250	39.30
Potassium Clavulanate equivalent to Clavulanic Acid	62.5	9.83
Polyplasdone XL (TM) dried	23.0	3.62
Syloid AL1 (Trade Mark)	23.0	3.62
Magnesium Stearate	4.5	0.71
Microcrystalline Cellulose	635.8	100.0
to		

The casing layer was applied to the cores by the following process:

1. **Granulation of casing material.**

- 1.1 The amoxycillin trihydrate was milled using a swing hammer mill at fast  
5 speed through an 0.063 inch screen with knives forward.
- 1.2 The amoxycillin trihydrate was blended with the potassium clavulanate,  
Polyplasdone, Syloid AL1 and part of the magnesium stearate and part of the  
microcrystalline cellulose.
- 1.3 The blend from 1.2 was slugged or roller compacted.
- 10 1.4 The compacts or flake from 1.3 were milled through a swing hammer mill  
operating at medium speed with knives forward and fitted with a 0.063" screen.
- 1.5 The granules from 1.4 were blended with the remaining magnesium stearate  
and remaining microcrystalline cellulose.

15 2. **Application of Casing Layer**

	Per Tablet (mg)
Enteric coated core (film coated)	494.2
Compression mix (tablet casting)	<u>635.8</u>
Tablet weight	<u>1130.0</u>
Hydroxypropyl Methyl Cellulose film coat	<u>27.0</u>
Film coat Tablet	1157.0

- The cores were fed to a specially designed tablet press, e.g. a Kilian RX machine adapted for core tablet manufacture, which dosed the compression mix  
20 'tablet casing' and a core into the tablet die followed by a further quantity of  
compression mix 'tablet casing' and the total core/compression mix was compressed  
to form a 1130mg tablet. The tablet press was designed to reject tablets which do

not contain a core. Alternatively individual tablets could be made by hand.

The tablet was aqueous film coated using a Hydroxypropyl Methyl Cellulose aqueous film coat, applying 27mg of coat to the tablet. This process was carried out in a coating drum, e.g. Accelacota, Driam or Hicota, using an air spray

5 process.

## Tablet 2

875mg amoxycillin as amoxycillin trihydrate

125mg of clavulanic acid as potassium clavulanate

10

### Casing Layer

Components	mg/tab	%
Amoxycillin trihydrate equivalent to Amoxycillin	625.0	78.13
Potassium Clavulanate equivalent to Clavulanic Acid	62.5	7.81
Polyplasdone XL dried	23.0	2.88
Syloid AL1	23.0	2.88
Magnesium Stearate	4.05	0.51
Microcrystalline Cellulose	800.0	to 100
to		

The casing layer material was prepared by a slugging or roller compaction process as described with respect to Tablet 1 above.

15

## 2. Application of Casing Layer

	Per Tablet (mg)
Enteric coated core (film coated) as described for Presentation 1	494.2
Compression mix (tablet casing)	<u>800.0</u>
	Tablet weight <u>1294.2</u>
Hydroxypropyl Methyl Cellulose film coat	<u>32.0</u>
	Film coat Tablet <u>1326.2</u>

The compression mix and cores were fed to a designed core tablet press equipped to reject tablets which do not contain a core. Alternatively tablets could be made individually by a hand press.

20

The tablets each containing a core were aqueous film coated in a drum coating unit, e.g. an Accelacota, Driam or Hicota with a Hydroxypropyl Methyl Cellulose Suspension to a film coat weight of 32mg.


**Claims:**

1. A tablet formulation comprising a core which includes a first pharmaceutically active material, the core being coated with a release retarding coating, the coated core being itself surrounded by a casing layer which includes a second pharmaceutically active material.
2. A tablet formulation according to claim 1 characterised in that the first and second pharmaceutically active materials in the tablet formulation each individually, and/or together, comprise a  $\beta$ -lactam antibiotic optionally together with a  $\beta$ -lactamase inhibitor.
3. A tablet formulation according to claim 2 characterised in that the first and second active materials both comprise amoxycillin, optionally together in combination with clavulanate.
4. A tablet formulation according to claim 3 characterised in that both the core and the casing layer contain clavulanate and amoxycillin.
5. A tablet formulation according to claim 3 characterised in that all of the clavulanate is contained in the casing layer.
6. A tablet formulation according to claim 3 characterised in that all of the clavulanate is contained in the core.
7. A tablet formulation according to any one of the preceding claims characterised in that the core and the casing layer both comprise a compact of compressed ingredients including the respective active materials.
8. A tablet formulation according to any one of the preceding claims characterised in that the release-retarding coating is an enteric polymer.
9. A tablet formulation according to any one of the preceding claims having one or more sub-coats beneath the release retarding coating layer.
10. A tablet formulation according to any one of the preceding claims having one or more over-coats above the release retarding coating layer.
11. A tablet formulation according to any one of claims 1 to 10, substantially as

hereinbefore described with reference to the accompanying drawing.

12. A method of preparing a pharmaceutical formulation as claimed in any one of claims 1 to 11, characterised by the steps of forming a core which includes a first  
5 pharmaceutically active material, the core being coated with a release-retarding coating, then coating the core with a casing layer which includes a second pharmaceutically active material.
13. A pharmaceutical formulation as claimed in any one of claims 1 to 11 for  
10 use as an active therapeutic substance.
14. A pharmaceutical formulation as claimed in any one of claims 1 to 11 for use in the treatment of bacterial infections.
- 15 15. The use of a formulation as claimed in any one of claims 1 to 11 in the manufacture of a medicament for use in the treatment of bacterial infections.
16. A method of treatment of bacterial infections in humans or animals which comprises the administration of an effective amount of a pharmaceutical formulation  
20 as claimed in any one of claims 1 to 11.

Fig. 1





## INTERNATIONAL SEARCH REPORT

 Inter. Appl. No.  
PCT/EP 95/01269

 A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K9/20 A61K31/43

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, A, 3 279 997 (HERBERT D. SCHNEIDER) 18 October 1966	1, 7, 8, 11-13
Y	see the whole document	2-6, 14-16
	---	
Y	WO, A, 94 06416 (JAGOTEC AG) 31 March 1994	2-6, 14-16
	see figure 2	
	see claims 1, 12	
	see page 7, line 7 - line 24	
	see page 11, line 15 - page 12, line 10	
	-----	

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & document member of the same patent family

Date of the actual completion of the international search

13 July 1995

Date of mailing of the international search report

21.07.95

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Ventura Amat, A

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 95/01269

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-3279997	18-10-66	NONE	
WO-A-9406416	31-03-94	AU-B- 4818293 CA-A- 2145513	12-04-94 31-03-94